Table 1.
Basic characteristics of breast cancer survivors.
| Characteristics |
All patients
(N = 744) |
Vaccinated group
(N = 94) |
Non-vaccinated group (N = 650) | P | ||
|---|---|---|---|---|---|---|
|
Planning vaccination
(N = 103) |
Hesitancy group
(N = 295) |
Refusal group
(N =2 52) |
||||
| Sex | 1.000 | |||||
| Male | 3 (0.40%) | 0 (0.00%) | 0 (0.00%) | 2 (0.68%) | 1 (0.40%) | |
| Female | 741 (99.60%) | 94 (100.00%) | 103 (100.00%) | 293 (99.32%) | 251 (99.60%) | |
| Age, years | 48.00 (40.00, 54.00) | 48.00 (42.00, 57.00) | 50.00 (42.00, 57.00) | 46.00 (40.00, 54.00) | 47.00 (40.00, 53.00) | 0.080 |
| <40 | 188 (25.27%) | 18 (19.15%) | 20 (19.42%) | 79 (26.78%) | 71 (28.17%) | 0.459 |
| 40~60 | 477 (64.11%) | 64 (68.09%) | 70 (67.96%) | 186 (63.05%) | 157 (62.30%) | |
| >60 | 79 (10.62%) | 12 (12.77%) | 13 (12.62%) | 30 (10.17%) | 24 (9.52%) | |
| Marital status | 0.912 | |||||
| Unmarried | 19 (2.55%) | 3 (3.19%) | 2 (1.94%) | 8 (2.71%) | 6 (2.38%) | |
| Married | 672 (90.32%) | 86 (91.49%) | 91 (88.35%) | 268 (90.85%) | 227 (90.08%) | |
| Others | 53 (7.12%) | 5 (5.32%) | 10 (9.71%) | 19 (6.44%) | 19 (7.54%) | |
| Educational level | 0.144 | |||||
| Middle school and below | 241 (32.39%) | 26 (27.66%) | 38 (36.89%) | 88 (29.83%) | 89 (35.32%) | |
| High school | 142 (19.09%) | 16 (17.02%) | 15 (14.56%) | 54 (18.31%) | 57 (22.62%) | |
| Junior college | 200 (26.88%) | 32 (34.04%) | 29 (28.16%) | 89 (30.17%) | 50 (19.84%) | |
| Bachelor and above | 161 (21.64%) | 20 (21.28%) | 21 (20.39%) | 64 (21.69%) | 56 (22.22%) | |
| Number of members in family | 0.388 | |||||
| 1~2 | 152 (20.43%) | 29 (30.85%) | 22 (21.36%) | 57 (19.32%) | 44 (17.46%) | |
| 3 | 275 (36.96%) | 30 (31.91%) | 41 (39.81%) | 104 (35.25%) | 100 (39.68%) | |
| 4 | 156 (20.97%) | 17 (18.09%) | 20 (19.42%) | 67 (22.71%) | 52 (20.63%) | |
| 5~ | 161 (21.64%) | 18 (19.15%) | 20 (19.42%) | 67 (22.71%) | 56 (22.22%) | |
| Annual income, yuan | 0.745 | |||||
| <20,000 | 195 (26.21%) | 20 (21.28%) | 25 (24.27%) | 78 (26.44%) | 72 (28.57%) | |
| 20,000~100,000 | 371 (49.87%) | 51 (54.26%) | 51 (49.51%) | 140 (47.46%) | 129 (51.19%) | |
| 110,000~200,000 | 111 (14.92%) | 12 (12.77%) | 18 (17.48%) | 49 (16.61%) | 32 (12.70%) | |
| >200,000 | 67 (9.01%) | 11 (11.70%) | 9 (8.74%) | 28 (9.49%) | 19 (7.54%) | |
| Medical cost | 0.45 | |||||
| Self-paid | 39 (5.24%) | 2 (2.13%) | 6 (5.83%) | 17 (5.76%) | 14 (5.56%) | |
| Insurance | 684 (91.94%) | 87 (92.55%) | 94 (91.26%) | 269 (91.19%) | 234 (92.86%) | |
| Others | 21 (2.82%) | 5 (5.32%) | 3 (2.91%) | 9 (3.05%) | 4 (1.59%) | |
| Duration of cancer, year | 0.003b, c | |||||
| <1 | 275 (36.96%) | 26 (27.66%) | 40 (38.83%) | 104 (35.25%) | 105 (41.67%) | |
| 1~3 | 326 (43.82%) | 35 (37.23%) | 45 (43.69%) | 139 (47.12%) | 107 (42.46%) | |
| 4~5 | 77 (10.35%) | 15 (15.96%) | 11 (10.68%) | 33 (11.19%) | 18 (7.14%) | |
| >5 | 66 (8.87%) | 18 (19.15%) | 7 (6.80%) | 19 (6.44%) | 22 (8.73%) | |
| Self-perceived feel | 0.024d | |||||
| Good | 231 (31.05%) | 34 (36.17%) | 42 (40.78%) | 80 (27.12%) | 75 (29.76%) | |
| General | 455 (61.16%) | 57 (60.64%) | 58 (56.31%) | 189 (64.07%) | 151 (59.92%) | |
| Bad | 58 (7.80%) | 3 (3.19%) | 3 (2.91%) | 26 (8.81%) | 26 (10.32%) | |
| Recent breast cancer-related treatments | 483 (64.92%) | 53 (56.38%) | 67 (65.05%) | 187 (63.39%) | 176 (69.84%) | 0.112 |
| Endocrine/targeted therapy | 298 (40.05%) | 25 (26.60%) | 36 (34.95%) | 130 (44.07%) | 107 (42.46%) | 0.013b, c |
| Chemotherapy | 134 (18.01%) | 21 (22.34%) | 17 (16.50%) | 40 (13.56%) | 56 (22.22%) | 0.040f |
| Radiotherapy | 51 (6.85%) | 1 (1.06%) | 9 (8.74%) | 20 (6.78%) | 21 (8.33%) | 0.095 |
| COVID-19 related characteristics | ||||||
| Had been infected by COVID-19 | 6 (0.81%) | 0 (0.00%) | 2 (1.94%) | 2 (0.68%) | 2 (0.79%) | 0.496 |
| Inform from communities or units | 437 (58.74%) | 78 (82.98%) | 67 (65.05%) | 170 (57.63%) | 122 (48.41%) | <0.001a, b, c, e |
| Existence of no vaccination in family, friends and colleges who met vaccination condition | 361 (48.52%) | 57 (60.64%) | 54 (52.43%) | 150 (50.85%) | 122 (48.41%) | 0.242 |
Post-hoc comparison with Bonferroni adjustment:
a
Vaccinated group vs. planning group;
b
Vaccinated group vs. hesitancy group;
c
Vaccinated group vs. refusal group;
d
Planning group vs. hesitancy group;
e
Planning group vs. refusal group;
f
Hesitancy group vs. refusal group.